Stocks & ETFs Screener: 200+ results (Biotechnology)
| Symbol | Industry | Market Cap | Fund. Score | Div. Score | Tech. Score | P/E | Return 12m vs S&P 500 |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie |
Biotechnology
Biologics, Immunology, Oncology |
394B | 48.1% | 73.9% | 84.9% | 170 | 13.4% |
| AMGN Amgen |
Biotechnology
Biologics, Oncology, Osteoporosis |
175B | 82.1% | 68.0% | 62.8% | 25.1 | 10.8% |
| GILD Gilead Sciences |
Biotechnology
HIV, COVID-19, Hepatitis, Oncology |
151B | 83.3% | 61.6% | 87.6% | 18.8 | 17.7% |
| VRTX Vertex |
Biotechnology
Cystic Fibrosis, Gene Therapy |
117B | 86.9% | - | 43.5% | 32.1 | -3.19% |
| REGN Regeneron |
Biotechnology
Eye, Dermatology, Asthma, Cancer |
79.4B | 75.8% | 14.9% | 14.7% | 18.0 | -5.67% |
| ARGX argenx |
Biotechnology
FcgRn-Blocker, MusK-Agonist |
53.2B | 71.3% | - | 83.6% | 36.6 | 15.0% |
| ALNY Alnylam |
Biotechnology
ONPATTRO, AMVUTTRA, GIVLAARI |
51.8B | 61.8% | - | 80.9% | - | 40.6% |
| HLN Haleon |
Biotechnology
Toothpaste, Vitamins, Cold-Relief |
44.1B | 69.5% | 53.1% | 40.3% | 22.0 | -9.50% |
| INSM Insmed |
Biotechnology
Liposomal Antibiotic, DPP1 |
37.5B | 32.4% | - | 89.4% | - | 114% |
| ONC BeiGene |
Biotechnology
BTK Inhibitor, PD-1 Antibody, PARP |
34.4B | 64.6% | - | 52.6% | 586 | 50.2% |
| NTRA Natera |
Biotechnology
Panorama, Horizon, Vistara |
31.3B | 47.9% | - | 77.3% | - | 24.2% |
| BIIB Biogen |
Biotechnology
Multiple Sclerosis, Spinal |
25.6B | 66.7% | - | -19.2% | 15.9 | -0.01% |
| UTHR United Therapeutics |
Biotechnology
Treprostinil, Orenitram, Unituxin |
23.4B | 91.8% | - | 76.3% | 19.6 | 19.9% |
| 22UA BioNTech SE |
Biotechnology
Cancer Vaccines, Immunotherapies |
22.3B | 11.0% | 1.0% | -66.5% | - | -38.6% |
| BNTX BioNTech SE |
Biotechnology
Cancer Immunotherapies |
22.2B | 12.9% | 1.0% | -56.4% | - | -29.1% |
| GMAB Genmab AS |
Biotechnology
Antibody Therapies, Oncological |
19.7B | 78.2% | - | 9.28% | 13.7 | 38.5% |
| INCY Incyte |
Biotechnology
JAKAFI, MONJUVI, PEMAZYRE |
19.1B | 90.3% | - | 39.8% | 16.5 | 23.5% |
| ROIV Roivant Sciences |
Biotechnology
Antibody, Small-Molecule, Inhaled |
15.2B | 31.6% | - | 89.7% | - | 60.2% |
| BIM Biomerieux |
Biotechnology
Diagnostic, Instruments, Reagents |
15.1B | 78.1% | 60.4% | 20.4% | 34.4 | -7.06% |
| RVMD Revolution |
Biotechnology
RAS Inhibitors, Companion |
14.7B | 24.9% | - | 75.0% | - | 56.1% |
| NBIX Neurocrine |
Biotechnology
Movement, Endocrine |
14.5B | 85.6% | - | 43.2% | 34.6 | -8.14% |
| BBIO BridgeBio Pharma |
Biotechnology
TTR Stabilizer, FGFR Inhibitor |
14.3B | 44.9% | - | 83.1% | - | 135% |
| SMMT Summit Therapeutics |
Biotechnology
Antibody, Immunotherapy, Oncology |
13.5B | 43.2% | - | 44.2% | - | -17.1% |
| MDGL Madrigal |
Biotechnology
Rezdiffra, Liver Therapy, MASH |
13.4B | 55.5% | - | 78.3% | - | 65.5% |
| MRNA Moderna |
Biotechnology
Vaccines, Oncology, Rare-Diseases |
13.2B | 22.6% | - | -77.2% | - | -30.3% |
| IONS Ionis |
Biotechnology
Triglyceride, Amyloidosis, SMA |
12.9B | 19.7% | 0.21% | 77.3% | - | 90.2% |
| ERF Eurofins |
Biotechnology
Testing, Laboratory, Services |
12.8B | 69.9% | 2.61% | 15.5% | 27.2 | 9.59% |
| EXEL Exelixis |
Biotechnology
Cabozantinib, Cobimetinib |
12.4B | 92.8% | - | 82.5% | 18.6 | 18.9% |
| ASND Ascendis Pharma AS |
Biotechnology
Growth Hormone |
12.4B | 35.7% | - | 79.3% | - | 28.0% |
| BMRN Biomarin |
Biotechnology
Enzyme, Replacement, Therapy |
11.4B | 85.6% | - | -62.5% | 22.0 | -21.2% |
| RNA Avidity Biosciences |
Biotechnology
Antibody-Oligonucleotide |
10.9B | 33.0% | - | 80.5% | - | 94.8% |
| ARWR Arrowhead |
Biotechnology
Plozasiran, Olpasiran, Fazirsiran |
9.42B | 49.1% | - | 45.1% | - | 202% |
| RGC Regencell |
Biotechnology
TCM Formulations, Neurocognitive |
8.53B | 36.9% | - | 79.0% | - | -14.6% |
| ABVX Abivax American |
Biotechnology
Obefazimod, Immunoregulatory |
8.19B | 39.9% | - | 82.3% | - | 1,508% |
| ABVX Abivax |
Biotechnology
Immunomodulator, Inflammatory |
8.16B | 31.9% | - | 74.5% | - | 1,346% |
| HALO Halozyme |
Biotechnology
Enzyme, Cancer, Immunodeficiency |
8.02B | 92.1% | - | 47.7% | 14.2 | 23.9% |
| GRFS Grifols |
Biotechnology
Immunoglobulin, Albumin |
7.65B | 65.2% | 40.6% | 25.7% | 13.8 | 3.03% |
| CYTK Cytokinetics |
Biotechnology
Cardiac Activator, Skeletal |
7.60B | 35.2% | - | 44.8% | - | 10.5% |
| RYTM Rhythm |
Biotechnology
Setmelanotide, Rare Obesity, MC4R |
7.47B | 42.2% | - | 95.1% | - | 71.3% |
| NUVL Nuvalent |
Biotechnology
ROS1 Inhibitor, ALK Inhibitor |
7.36B | 28.8% | - | 82.3% | - | 6.82% |
| MRUS Merus BV |
Biotechnology
Bispecific Antibodies, BIZENGRI |
7.34B | 28.5% | - | 93.8% | - | 95.0% |
| CDTX Cidara Therapeutics |
Biotechnology
Antifungal, Antiviral, Oncology |
6.93B | 23.5% | - | 81.3% | - | 706% |
| KRYS Krystal Biotech |
Biotechnology
Gene, Therapy, Topical, Wound, Skin |
6.77B | 88.9% | - | 78.4% | 34.9 | 34.6% |
| PRAX Praxis Precision |
Biotechnology
Ulixacaltamide, Vormatrigine |
6.73B | 31.6% | - | 60.2% | - | 204% |
| KYMR Kymera Therapeutics |
Biotechnology
IRAK4, STAT6, TYK2, Protein |
6.37B | 29.1% | - | 75.0% | - | 75.0% |
| PTCT PTC Therapeutics |
Biotechnology
Translarna, Emflaza, Upstaza |
6.12B | 65.7% | - | 65.3% | 8.87 | 45.7% |
| COGT Cogent Biosciences |
Biotechnology
Kinase Inhibitor, FGFR Inhibitor |
6.07B | 49.6% | - | 73.5% | - | 342% |
| BLTE Belite Bio |
Biotechnology
Oral Therapy, Stargardt |
5.80B | 32.4% | - | 92.7% | - | 110% |
| PCVX Vaxcyte |
Biotechnology
Pneumococcal, Streptococcus |
5.72B | 27.0% | - | -6.86% | - | -53.1% |
| PTGX Protagonist |
Biotechnology
Peptide, Hematology, Inflammation |
5.36B | 64.0% | - | 90.6% | 130 | 86.7% |
| APGE Apogee |
Biotechnology
Monoclonal Antibody, Atopic |
5.28B | 35.5% | - | 75.3% | - | 39.0% |
| IMVT Immunovant |
Biotechnology
Monoclonal Antibodies, Autoimmune |
5.27B | 26.3% | - | 30.3% | - | -11.3% |
| CRSP Crispr Therapeutics |
Biotechnology
Gene-Edited Cell Therapy, CAR T |
5.22B | 31.9% | - | 38.7% | - | 19.2% |
| TGTX TG Therapeutics |
Biotechnology
Briumvi, Ublituximab, BTK |
4.92B | 67.6% | - | 38.6% | 11.2 | -18.6% |
| ALKS Alkermes |
Biotechnology
Schizophrenia, Bipolar, Alcohol |
4.73B | 89.8% | - | 3.87% | 14.2 | -17.5% |
| SRRK Scholar Rock |
Biotechnology
Monoclonal Antibodies, Inhibitor |
4.61B | 26.5% | - | 46.6% | - | -10.8% |
| CELC Celcuity |
Biotechnology
Cancer Test, Therapy Candidate |
4.59B | 24.8% | - | 82.2% | - | 605% |
| ACAD ACADIA |
Biotechnology
Antipsychotic, Rett |
4.56B | 86.2% | - | 59.9% | 17.3 | 38.5% |
| CRNX Crinetics |
Biotechnology
Paltusotine, Atumelnant, CRN09682 |
4.53B | 21.7% | - | 49.7% | - | -22.6% |
| ADMA ADMA Biologics |
Biotechnology
IVIG, Immune Globulin, Hepatitis |
4.49B | 84.9% | - | 56.2% | 21.9 | -6.03% |
| INDV Indivior Ordinary |
Biotechnology
Suboxone, Sublocade, Subutex, Opvee |
4.44B | 74.0% | 2.63% | 65.6% | 36.3 | 161% |
| GPCR Structure |
Biotechnology
GSBR-1290, ACCG-2671, ANPA-0073 |
4.41B | 33.5% | - | 55.5% | - | 113% |
| LEGN Legend Biotech |
Biotechnology
CAR-T, Oncology, Myeloma |
4.05B | 28.3% | - | -56.6% | - | -42.5% |
| NAMS NewAmsterdam |
Biotechnology
Obicetrapib, Ezetimibe, CETP |
3.98B | 26.5% | - | 82.7% | - | 19.8% |
| VKTX Viking Therapeutics |
Biotechnology
VK2809, VK2735, VK5211, VK0214 |
3.98B | 40.6% | - | 45.8% | - | -26.5% |
| ACLX Arcellx |
Biotechnology
Anitocabtagene Autoleucel |
3.95B | 39.8% | - | 60.1% | - | -27.1% |
| LGND Ligand |
Biotechnology
Infectious, Oncology, Nephrology |
3.91B | 50.1% | 0.14% | 86.6% | 87.8 | 48.2% |
| CNTA Centessa |
Biotechnology
OX2R Agonist, Neurological Drugs |
3.67B | 33.1% | - | 77.6% | - | 23.1% |
| VERA Vera Therapeutics |
Biotechnology
Atacicept, Mab, Dual-Inhibitor |
3.64B | 25.1% | 3.50% | 50.6% | - | 8.86% |
| GRAL GRAIL |
Biotechnology
Cancer Screening, Diagnostic Aid |
3.55B | 40.1% | - | 91.9% | - | 317% |
| ARQT Arcutis |
Biotechnology
Topical Cream, Topical Foam, JAK1 |
3.43B | 41.9% | - | 54.5% | - | 67.3% |
| DYN Dyne Therapeutics |
Biotechnology
Antisense Oligos, FORCE Platform |
3.42B | 29.6% | - | 31.3% | - | -27.1% |
| VCYT Veracyte |
Biotechnology
Thyroid, Prostate, Bladder |
3.39B | 63.6% | - | 32.4% | 113 | -10.5% |
| FOLD Amicus Therapeutics |
Biotechnology
Galafold, Pombiliti, Opfolda, Gene |
3.36B | 52.2% | - | 14.4% | - | 23.4% |
| XENE Xenon |
Biotechnology
Kv7 Opener, Phase 3, Epilepsy |
3.32B | 29.5% | - | 34.2% | - | -0.23% |
| MIRM Mirum |
Biotechnology
LIVMARLI, Cholbam, Chenodal |
3.31B | 47.5% | - | 92.8% | - | 63.9% |
| RARE Ultragenyx |
Biotechnology
Biologic, Gene Therapy, Antibody |
3.20B | 36.5% | - | -55.5% | - | -33.5% |
| APLS Apellis |
Biotechnology
Therapeutic, Complement |
3.20B | 75.9% | - | -53.5% | 70.3 | -36.2% |
| KNSA Kiniksa |
Biotechnology
ARCALYST, Vixarelimab, KPL-387 |
3.18B | 66.8% | - | 95.0% | 93.3 | 79.4% |
| TVTX Travere |
Biotechnology
Medication, Tablets, Enzyme |
3.09B | 27.4% | - | 46.3% | - | 76.2% |
| NUVB Nuvation Bio |
Biotechnology
Taletrectinib, Safusidenib |
3.08B | 37.0% | - | 67.9% | - | 199% |
| CGON CG Oncology |
Biotechnology
Oncolytic Virus, Immunotherapy |
3.05B | 31.9% | - | 26.5% | - | 21.6% |
| IRON Disc Medicine |
Biotechnology
Porphyria Drug, Anemia Drug |
3.02B | 35.8% | - | 54.2% | - | 6.87% |
| VRDN Viridian |
Biotechnology
Monoclonal Antibody, Thyroid Eye |
3.02B | 46.9% | - | 33.4% | - | 39.5% |
| CPRX Catalyst |
Biotechnology
Firdapse, Fycompa, Ruzurgi, Agamree |
2.95B | 91.5% | - | 27.2% | 14.1 | -4.16% |
| MLYS Mineralys |
Biotechnology
Phase II Inhibitor, Oral |
2.93B | 30.7% | - | 72.4% | - | 165% |
| IDYA Ideaya Biosciences |
Biotechnology
Oncology, Kinase, Inhibitor, ADC |
2.92B | 22.7% | - | 68.6% | - | 19.2% |
| BEAM Beam Therapeutics |
Biotechnology
Base-Editing Therapeutics, Sickle |
2.72B | 27.5% | - | -29.1% | - | -17.3% |
| RCUS Arcus Biosciences |
Biotechnology
Cancer, Immunotherapy |
2.71B | 29.9% | - | 16.4% | - | 21.6% |
| SLNO Soleno Therapeutics |
Biotechnology
Diazoxide, Choline, Tablet, Rare |
2.65B | 41.4% | - | 58.2% | - | -7.16% |
| DNLI Denali Therapeutics |
Biotechnology
RIPK1 Inhibitor, eIF2B Activator |
2.63B | 25.0% | - | -44.2% | - | -30.9% |
| OLMA Olema |
Biotechnology
Palazestrant, OP-3136, KAT6 |
2.61B | 35.5% | - | 70.0% | - | 275% |
| SYRE Spyre Therapeutics |
Biotechnology
Monoclonal Antibodies |
2.60B | 29.9% | - | 39.9% | - | 20.4% |
| RXRX Recursion |
Biotechnology
Drug Discovery Platform |
2.44B | 30.1% | - | -62.8% | - | -46.7% |
| EWTX Edgewise |
Biotechnology
EDG-5506, EDG-7500, Oral |
2.24B | 29.5% | - | 20.2% | - | -38.0% |
| SRPT Sarepta |
Biotechnology
RNA Therapeutics, Duchenne |
2.22B | 30.4% | - | -74.0% | - | -84.4% |
| IMNM Immunome |
Biotechnology
Gamma Secretase Inhibitor, ADC |
2.20B | 45.2% | - | 71.8% | - | 69.2% |
| AUPH Aurinia |
Biotechnology
Immunosuppressant, Lupus |
2.10B | 93.8% | - | 71.1% | 28.4 | 54.7% |
| GLPG Galapagos |
Biotechnology
CAR-T, Oncology, Immunology |
2.08B | 25.3% | - | -15.7% | - | -7.60% |
| GLPG Galapagos |
Biotechnology
Medicine, Oncology, Immunology |
2.08B | 37.8% | - | 0.66% | - | 3.89% |
| IBRX Immunitybio |
Biotechnology
Immunotherapy, Vaccine, Cytokine |
2.05B | 65.8% | - | -69.9% | - | -32.8% |
| ZYME Zymeworks Common |
Biotechnology
Zanidatamab, Bispecific Antibody |
2.00B | 29.8% | - | 73.2% | - | 60.3% |
| SION Sionna |
Biotechnology
Galicaftor, Navocaftor, SION-109 |
1.97B | 37.1% | - | 93.1% | - | 110% |
| NRIX Nurix Therapeutics |
Biotechnology
BTK Degrader, IRAK4 Degrader |
1.96B | 35.8% | - | 11.2% | - | -17.5% |
| MESO Mesoblast |
Biotechnology
Stem-Cell Therapy, Inflammation |
1.94B | 36.8% | - | 38.3% | - | -4.84% |
| ZBIO Zenas BioPharma |
Biotechnology
Bifunctional Monoclonal Antibody |
1.91B | 31.4% | - | 89.9% | 2.61 | 282% |
| ZLAB Zai Lab |
Biotechnology
Oncology, Immunology |
1.90B | 31.9% | - | -44.7% | - | -43.7% |
| TWST Twist Bioscience |
Biotechnology
Synthetic DNA, Gene Fragments |
1.90B | 35.8% | - | -16.2% | - | -39.9% |
| STOK Stoke Therapeutics |
Biotechnology
Antisense, Oligonucleotide |
1.88B | 73.2% | - | 69.8% | 48.5 | 134% |
| VCEL Vericel Ord |
Biotechnology
Cartilage, Skin, Burn, Autologous |
1.84B | 61.8% | - | -7.90% | 140 | -44.0% |
| IMCR Immunocore Holdings |
Biotechnology
Immunotherapy, Oncology, Melanoma |
1.81B | 41.2% | - | 5.08% | - | 9.88% |
| SNDX Syndax |
Biotechnology
Menin Inhibitor, CSF-1R Antibody |
1.81B | 36.6% | - | 13.8% | - | 39.3% |
| DNTH Dianthus |
Biotechnology
Monoclonal Antibody, C1s |
1.78B | 26.8% | - | 65.4% | - | 57.1% |
| ALVO Alvotech |
Biotechnology
Biosimilar, Autoimmune, Oncology |
1.72B | 36.5% | - | -72.2% | 24.0 | -67.2% |
| CLDX Celldex |
Biotechnology
Antibody, Monoclonal, Bispecific |
1.71B | 40.4% | - | -12.2% | - | -8.32% |
| BCRX BioCryst |
Biotechnology
Antiviral, Hae, Complement, Protein |
1.60B | 71.5% | - | -40.1% | - | -17.3% |
| TSHA Taysha Gene |
Biotechnology
Gene Therapy, Rett Syndrome, CLN1 |
1.58B | 47.2% | - | 63.4% | - | 167% |
| PHVS Pharvaris BV |
Biotechnology
Bradykinin, Antagonist |
1.56B | 24.4% | - | 68.0% | - | 16.7% |
| MNKD MannKind |
Biotechnology
Inhaled Insulin, Insulin Delivery |
1.56B | 64.0% | - | 9.09% | 50.7 | -27.8% |
| ORKA Oruka Therapeutics |
Biotechnology
Monoclonal Antibody |
1.54B | 29.4% | 1.0% | 58.1% | - | 29.0% |
| ATAI ATAI Life Sciences |
Biotechnology
Psychedelic, Serotonergic |
1.50B | 38.2% | - | 56.0% | - | 208% |
| QURE Uniqure |
Biotechnology
Gene Therapy, Hemophilia B |
1.49B | 36.0% | - | 22.9% | - | 18.5% |
| MEDCL Medincell |
Biotechnology
Schizophrenia, Postoperative Pain |
1.49B | 57.7% | - | 86.2% | - | 26.5% |
| AGIO Agios Pharm |
Biotechnology
Mitapivat, Tebapivat, AG-181 |
1.48B | 34.6% | - | -5.20% | - | -40.6% |
| BHVN Biohaven |
Biotechnology
Troriluzole, Taldefgrobep |
1.48B | 31.9% | - | -47.4% | - | -75.2% |
| CAPR Capricor |
Biotechnology
Cell Therapy, Exosome Platform |
1.44B | 28.4% | - | 46.4% | - | 74.8% |
| NNNN Anbio |
Biotechnology
Antigen Tests, Immunoassay |
1.42B | 66.4% | - | 82.9% | 647 | 428% |
| ARDX Ardelyx |
Biotechnology
IBS-C Therapy, Phosphate |
1.41B | 33.7% | - | 55.0% | - | 8.20% |
| KOD Kodiak Sciences |
Biotechnology
Anti-VEGF, Biopolymer Conjugate |
1.40B | 46.6% | - | 58.6% | - | 154% |
| BTX BlackRock |
Biotechnology
Tech, Private Equity, Mutual Fund |
1.40B | 34.0% | 87.2% | 28.3% | 54.6 | -13.2% |
| RLAY Relay Therapeutics |
Biotechnology
RLY-2608, Lirafugratinib |
1.39B | 47.4% | - | -12.6% | - | 63.6% |
| PGEN Precigen |
Biotechnology
Gene Therapy, UltraCAR-T |
1.36B | 34.7% | - | 62.8% | - | 366% |
| IMTX Immatics |
Biotechnology
TCR Cell Therapy, Bispecific |
1.34B | 21.7% | - | 34.4% | - | 23.5% |
| ANAB AnaptysBio |
Biotechnology
Antibody, Autoimmune |
1.33B | 24.4% | - | 60.2% | - | 206% |
| SVRA Savara |
Biotechnology
Molgramostim, Proteinosis |
1.31B | 23.0% | - | 83.2% | - | 69.3% |
| DVAX Dynavax |
Biotechnology
Hepatitis Vaccine, Adjuvant |
1.28B | 38.5% | - | -16.5% | - | -25.9% |
| SANA Sana Biotechnology |
Biotechnology
Allogeneic Islet Therapy, CAR-T |
1.27B | 35.2% | - | 33.2% | - | 137% |
| UPB Upstream Bio |
Biotechnology
Clinical-Stage, Therapeutic |
1.26B | 38.1% | - | 75.0% | - | 39.2% |
| MBX MBX Biosciences |
Biotechnology
Hypoparathyroidism, Hypoglycemia |
1.24B | 31.9% | - | 72.4% | 3.61 | 33.7% |
| TYRA Tyra Biosciences |
Biotechnology
FGFR Inhibitor, Precision |
1.23B | 29.2% | - | 63.0% | - | 54.9% |
| MNMD Mind Medicine |
Biotechnology
MM120, MM402, Anxiety, ADHD, Autism |
1.17B | 31.4% | - | 72.0% | - | 69.2% |
| CSTL Castle Biosciences |
Biotechnology
Melanoma, Squamous, Uveal |
1.16B | 53.5% | - | 37.4% | - | 25.0% |
| ALMS Alumis |
Biotechnology
TYK2 Inhibitor, Psoriasis, Lupus |
1.15B | 50.9% | - | -31.7% | - | 16.9% |
| TNGX Tango Therapeutics |
Biotechnology
PRMT5 Inhibitor, Glioblastoma |
1.15B | 32.3% | - | 35.5% | - | 126% |
| OCS Oculis Holding |
Biotechnology
OCS-01, OCS-02, OCS-05 |
1.15B | 25.3% | - | 60.5% | - | 4.0% |
| PHARM Pharming |
Biotechnology
Recombinant C1-Inhibitor |
1.14B | 66.7% | - | 37.7% | - | 41.0% |
| PVLA Palvella |
Biotechnology
Rapamycin, Gel, Microcystic |
1.14B | 25.5% | - | 38.7% | - | 614% |
| CVAC CureVac |
Biotechnology
Mrna, Vaccines, Oncology |
1.13B | 26.6% | - | -0.09% | 7.46 | 21.5% |
| XNCR Xencor |
Biotechnology
Monoclonal Antibodies, Bispecific |
1.11B | 12.6% | - | -45.5% | - | -46.2% |
| NBTX Nanobiotix |
Biotechnology
Nanoparticles, Radiotherapy |
1.08B | 49.2% | - | 78.2% | - | 565% |
| URGN UroGen Pharma |
Biotechnology
Jelmyto, UGN-102, UGN-103 |
1.07B | 48.5% | - | 69.3% | - | 86.7% |
| EVO Evotec SE |
Biotechnology
Small-Molecule Compounds |
1.07B | 23.6% | 7.69% | -74.7% | - | -39.9% |
| NANO Nanobiotix S.A |
Biotechnology
Nanoparticle, Radiotherapy |
1.06B | 36.2% | - | 76.8% | - | 467% |
| NVAX Novavax |
Biotechnology
Vaccine, Adjuvant, Nanoparticle |
1.06B | 40.4% | - | -32.5% | 3.25 | -32.8% |
| MDXG MiMedx |
Biotechnology
Placental Allografts, Wound Care |
1.04B | 86.0% | - | 22.6% | 26.1 | -35.5% |
| OPK Opko Health |
Biotechnology
Diagnostics, Laboratory-Testing |
1.04B | 21.0% | - | -19.4% | - | -25.9% |
| CDNA CareDx |
Biotechnology
AlloSure, AlloMap, AlloSeq |
1.04B | 50.0% | - | -0.28% | 15.2 | -18.3% |
| ERAS Erasca |
Biotechnology
Naporafenib, ERAS-0015, ERAS-4001 |
1.04B | 34.9% | - | 1.32% | - | 16.8% |
| GLUE Monte Rosa |
Biotechnology
MRT-2359, MRT-6160, MRT-8102, CDK2 |
1.03B | 71.5% | - | 45.4% | 49.5 | 97.2% |
| NTLA Intellia |
Biotechnology
In-Vivo CRISPR, CAR-T, NK Cell |
1.02B | 32.6% | - | -53.2% | - | -33.5% |
| BCAX Bicara |
Biotechnology
Ficerafusp Alfa, Bifunctional |
1.01B | 29.8% | - | -5.12% | 3.41 | -20.0% |
| BBOT BridgeBio Oncology |
Biotechnology
KRAS Inhibitor, HER2 Therapy |
1.01B | 47.6% | - | 85.0% | - | 9.01% |
| ABCL Abcellera Biologics |
Biotechnology
Antibody, Metabolic, Autoimmune |
1.00B | 15.6% | - | -19.6% | - | 7.97% |
| IOVA Iovance |
Biotechnology
Amtagvi, Lifileucel, Proleukin |
1.00B | 42.7% | - | -72.6% | - | -67.7% |
| SPRY ARS |
Biotechnology
Epinephrine, Nasal Spray |
995M | 29.8% | - | 2.99% | - | -15.9% |
| AVBP ArriVent |
Biotechnology
Firmonertinib, ARR-217, ARR-002 |
976M | 40.1% | - | -0.02% | - | -26.7% |
| MLTX MoonLake |
Biotechnology
Nanobody, IL-17A, IL-17F |
949M | 26.9% | - | 3.96% | - | -77.5% |
| RAPT RAPT Therapeutics |
Biotechnology
CCR4 Antagonist, Inflammation |
937M | 27.9% | - | -17.4% | - | 117% |
| KURA Kura Oncology |
Biotechnology
Menin Inhibitor, Farnesyl |
919M | 53.8% | - | 7.18% | - | 3.12% |
| 5CV CureVac |
Biotechnology
mRNA, Prophylactic Vaccines |
907M | 27.2% | - | -22.2% | 6.17 | 10.1% |
| GERN Geron |
Biotechnology
Telomerase Inhibitor |
894M | 27.3% | - | -53.0% | - | -66.0% |
| ABUS Arbutus Biopharma |
Biotechnology
RNAi Therapeutic, PD-L1 Inhibitor |
892M | 29.5% | - | 71.1% | - | 25.3% |
| ORIC Oric |
Biotechnology
ORIC-114, ORIC-944, ORIC-533 |
888M | 35.0% | - | 31.5% | - | -15.2% |
| CMPX Compass |
Biotechnology
Tovecimig, CTX-471, CTX-8371 |
882M | 32.7% | - | 30.9% | - | 191% |
| ESPR Esperion |
Biotechnology
Bempedoic Acid, Ezetimibe Combo |
865M | 55.7% | - | -3.18% | - | 48.0% |
| JANX Janux Therapeutics |
Biotechnology
JANX007, JANX008, TRACTr, TRACIr |
848M | 38.3% | - | -17.1% | - | -78.7% |
| DAWN Day One |
Biotechnology
Tovorafenib, DAY301, VRK1 Inhibitor |
847M | 30.8% | - | -58.7% | - | -35.2% |
| GOSS Gossamer Bio |
Biotechnology
Seralutinib, GB002, PAH Therapy |
826M | 36.0% | - | 48.7% | - | 227% |
| IVA Inventiva S.A |
Biotechnology
Lanifibranor, Odiparcil, TGF-Beta |
816M | 46.2% | - | 0.42% | - | 43.4% |
| DBVT DBV Technologies |
Biotechnology
Epicutaneous, Immunotherapy |
814M | 38.3% | - | 37.2% | - | 391% |
| VIR Vir Biotechnology |
Biotechnology
Antibodies, Vaccines, T-Cell |
801M | 28.5% | - | -71.5% | - | -30.3% |
| LYEL Lyell Immunopharma |
Biotechnology
CAR-T, Dual-Target, Solid Tumor |
794M | 22.3% | - | -9.63% | - | 159% |
| GHRS GH Research |
Biotechnology
Mebufotenin, Depression |
787M | 24.0% | - | 39.0% | - | 55.6% |
| KALV Kalvista |
Biotechnology
Plasma Kallikrein Inhibitor, Oral |
770M | 39.7% | - | 63.2% | - | 52.4% |
| RIGL Rigel |
Biotechnology
Kinase, Inhibitor |
763M | 93.2% | - | 68.5% | 6.79 | 119% |
| REPL Replimune |
Biotechnology
Oncolytic Immunotherapy, RP1, RP2 |
758M | 28.2% | - | -69.9% | - | -32.7% |
| LXEO Lexeo |
Biotechnology
Gene Therapy, Cardiomyopathy |
755M | 33.8% | - | 12.6% | - | 43.6% |
| PROK ProKidney |
Biotechnology
Cell Therapy, Autologous Renal |
740M | 41.7% | - | -13.7% | - | 26.4% |
| ANNX Annexon |
Biotechnology
Antibody, Fragment |
732M | 36.7% | - | -6.02% | - | -17.3% |
| ATXS Astria Therapeutics |
Biotechnology
Monoclonal, Antibody, Plasma |
726M | 35.6% | - | 17.2% | - | 15.8% |
| VLA Valneva SE |
Biotechnology
Japanese Encephalitis, Cholera |
721M | 25.4% | - | -15.2% | - | 62.8% |
| CTMX CytomX Therapeutics |
Biotechnology
Antibody-Drug Conjugate, T-Cell |
700M | 60.9% | - | 56.6% | 13.8 | 229% |
| PRME Prime Medicine |
Biotechnology
Gene Editing, Prime Editing |
675M | 40.6% | - | -23.6% | - | 12.2% |
| ORGO Organogenesis |
Biotechnology
Wound Care, Skin Substitutes |
669M | 30.1% | - | 51.2% | - | 54.5% |
| RGNX Regenxbio |
Biotechnology
Gene,Therapy,AAV,Platform,Pipeline |
667M | 14.7% | - | -0.22% | - | 66.1% |
| EBS Emergent |
Biotechnology
Vaccine, Antitoxin, Auto-Injector |
663M | 50.2% | 0.14% | 15.2% | 9.41 | 31.5% |
| MGTX MeiraGTx Holdings |
Biotechnology
Gene Therapy, Ocular Diseases |
653M | 36.3% | - | 33.6% | - | 10.4% |
| MYGN Myriad Genetics |
Biotechnology
Hereditary-Cancer, Risk |
630M | 36.3% | 0.08% | -71.6% | - | -58.9% |
| KROS Keros Therapeutics |
Biotechnology
Therapeutics, Clinical |
617M | 74.4% | - | -11.8% | 13.0 | 6.70% |
| DRUG Bright Minds |
Biotechnology
5-HT2C-agonist, BMB-101, BMB-201 |
607M | 28.7% | - | 74.0% | - | 86.1% |